concept

Ratio 2-OHE:16-OHE1

Two estrogen metabolites, in particular, 16-OHE1 and 2-OHE, have contrasting cellular activities with 16-OHE1 being an estrogen agonist, whereas 2-OHE is an estrogen antagonist. Some other estrogen metabolites, 4-OHE1 and 4-OHE2, are also estrogen agonists but their relative concentrations are too low to be of physiological significance. Several studies using cell culture models have demonstrated the proliferative effects of 16-OHE1 and the antiproliferative effects of 2-OHE (1–4). The relative concentration of 2-OHE:16-OHE1 can increase or decrease the risk of developing hormone responsive cancers (breast and cervical) (1,2,5–9) (Fig. 1) and is used as a predictive biomarker for these cancers (10).

Ref:
Rajoria S, Suriano R, Parmar PS, Wilson YL, Megwalu U, Moscatello A, Bradlow HL, Sepkovic DW, Geliebter J, Schantz SP, Tiwari RK. 3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid. 2011 Mar;21(3):299-304. doi: 10.1089/thy.2010.0245. Epub 2011 Jan 22. PMID: 21254914; PMCID: PMC3048776.

0 confidence points
0 comments
Added on Jan 2, 2024 by Barbara Van De Keer

Join Ninatoka!!

NinatoKa's goal is to support you as a therapist in unravelling the illness pathway from symptoms to cause, and to help you detect potential interventions.

Go to Explore to start your discovery!

Go to Learn to scroll through newly added data.

Go to Contribute to contribute to the Ninatoka database.

You can rate content up or down and add comments if you agree or disagree.